NEK1 variants confer susceptibility to amyotrophic lateral sclerosis

  • Nat Genet. 2016 Sep;48(9):1037-42. doi: 10.1038/ng.3626.
Kevin P Kenna  1 Perry T C van Doormaal  2 Annelot M Dekker  2 Nicola Ticozzi  3  4 Brendan J Kenna  1 Frank P Diekstra  2 Wouter van Rheenen  2 Kristel R van Eijk  2 Ashley R Jones  5 Pamela Keagle  1 Aleksey Shatunov  5 William Sproviero  5 Bradley N Smith  5 Michael A van Es  2 Simon D Topp  5 Aoife Kenna  1 Jack W Miller  5 Claudia Fallini  1 Cinzia Tiloca  3  6 Russell L McLaughlin  7 Caroline Vance  5 Claire Troakes  5 Claudia Colombrita  3  4 Gabriele Mora  8 Andrea Calvo  9 Federico Verde  3  4 Safa Al-Sarraj  5 Andrew King  5 Daniela Calini  3 Jacqueline de Belleroche  10 Frank Baas  11 Anneke J van der Kooi  12 Marianne de Visser  12 Anneloor L M A Ten Asbroek  11 Peter C Sapp  1 Diane McKenna-Yasek  1 Meraida Polak  13 Seneshaw Asress  13 José Luis Muñoz-Blanco  14 Tim M Strom  15 Thomas Meitinger  16 Karen E Morrison  17 SLAGEN Consortium Giuseppe Lauria  18 Kelly L Williams  19 P Nigel Leigh  20 Garth A Nicholson  19  21 Ian P Blair  19 Claire S Leblond  22 Patrick A Dion  22 Guy A Rouleau  22 Hardev Pall  23  24 Pamela J Shaw  25 Martin R Turner  25 Kevin Talbot  25 Franco Taroni  26 Kevin B Boylan  27 Marka Van Blitterswijk  28 Rosa Rademakers  28 Jesús Esteban-Pérez  29  30 Alberto García-Redondo  29  30 Phillip Van Damme  31  32 Wim Robberecht  31  32 Adriano Chio  9 Cinzia Gellera  26 Carsten Drepper  33  34 Michael Sendtner  33 Antonia Ratti  3  4 Jonathan D Glass  13 Jesús S Mora  35 Nazli A Basak  36 Orla Hardiman  7 Albert C Ludolph  37 Peter M Andersen  38 Jochen H Weishaupt  37 Robert H Brown Jr  1 Ammar Al-Chalabi  5 Vincenzo Silani  3  4 Christopher E Shaw  5 Leonard H van den Berg  2 Jan H Veldink  2 John E Landers  1
Affiliations
  • 1. Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
  • 2. Department of Neurology Brain Centre, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • 3. Department of Neurology, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • 4. Department of Pathophysiology and Transplantation, 'Dino Ferrari' Center, Università degli Studi di Milano, Milan, Italy.
  • 5. Maurice Wohl Clinical Neuroscience Institute, King's College London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, London, UK.
  • 6. Doctoral School in Molecular Medicine, Department of Sciences and Biomedical Technologies, Università degli Studi di Milano, Milan, Italy.
  • 7. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • 8. Salvatore Maugeri Foundation, IRCSS, Scientific Institute of Milano, Milan, Italy.
  • 9. 'Rita Levi Montalcini' Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.
  • 10. Neurogenetics Group, Division of Brain Sciences, Imperial College London, London, UK.
  • 11. Department of Clinical Genetics, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
  • 12. Department of Neurogenetics and Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
  • 13. Department of Neurology, Emory University, Atlanta, Georgia, USA.
  • 14. Unidad de ELA, Instituto de Investigación Hospital Gregorio Marañón de Madrid, Madrid, Spain.
  • 15. Institute of Human Genetics, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
  • 16. Institute of Human Genetics, Technische Universität München, Munich, Germany.
  • 17. Faculty of Medicine, University of Southampton, Southampton, UK.
  • 18. 3rd Neurology Unit, Motor Neuron Diseases Center, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy.
  • 19. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • 20. Trafford Centre for Medical Research, Brighton and Sussex Medical School, Falmer, UK.
  • 21. ANZAC Research Institute, Concord Hospital, University of Sydney, Sydney, New South Wales, Australia.
  • 22. Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
  • 23. Institute of Clinical Studies, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
  • 24. Department of Neurology, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, UK.
  • 25. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • 26. Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico 'Carlo Besta', Milan, Italy.
  • 27. Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • 28. Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • 29. Unidad de ELA, Instituto de Investigación Hospital 12 de Octubre de Madrid, Madrid, Spain.
  • 30. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) U-723, Madrid, Spain.
  • 31. Laboratory of Neurobiology, Department of Neurosciences, KU Leuven and Vesalius Research Centre, VIB, Leuven, Belgium.
  • 32. Department of Neurology, University Hospitals, Leuven, Belgium.
  • 33. Institute of Clinical Neurobiology, University Hospital Würzburg, Würzburg, Germany.
  • 34. Department of Child and Adolescent Psychiatry, University Hospital of Würzburg, Würzburg, Germany.
  • 35. ALS Unit/Neurology, Hospital San Rafael, Madrid, Spain.
  • 36. NDAL, Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey.
  • 37. Neurology Department, Ulm University, Ulm, Germany.
  • 38. Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Abstract

To identify genetic factors contributing to amyotrophic lateral sclerosis (ALS), we conducted whole-exome analyses of 1,022 index familial ALS (FALS) cases and 7,315 controls. In a new screening strategy, we performed gene-burden analyses trained with established ALS genes and identified a significant association between loss-of-function (LOF) NEK1 variants and FALS risk. Independently, autozygosity mapping for an isolated community in the Netherlands identified a NEK1 p.Arg261His variant as a candidate risk factor. Replication analyses of sporadic ALS (SALS) cases and independent control cohorts confirmed significant disease association for both p.Arg261His (10,589 samples analyzed) and NEK1 LOF variants (3,362 samples analyzed). In total, we observed NEK1 risk variants in nearly 3% of ALS cases. NEK1 has been linked to several cellular functions, including cilia formation, DNA-damage response, microtubule stability, neuronal morphology and axonal polarity. Our results provide new and important insights into ALS etiopathogenesis and genetic etiology.